Sensitivity and specificity of diagnostic accuracy in alzheimer's disease: A synthesis of existing evidence

American Journal of Alzheimer's Disease and other Dementias

Volumn 28, Issue 4, 2013, Pages 337-347

  Gaugler, Joseph E ^a   Kane, Robert L ^b   Johnston, Joseph A ^c   Sarsour, Khaled ^d  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d GENENTECH INC   (United States)

Author keywords

clinical; dementia; meta analysis; sensitivity; specificity; systematic review

Indexed keywords

TAU PROTEIN;

ALZHEIMER DISEASE; CEREBROSPINAL FLUID; COMPARATIVE EFFECTIVENESS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; META ANALYSIS (TOPIC); NEUROPATHOLOGY; POSITRON EMISSION TOMOGRAPHY; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW (TOPIC);

EID: 84879736006     PISSN: 15333175     EISSN: 19382731     Source Type: Journal    
DOI: 10.1177/1533317513488910     Document Type: Review

References (57)

1. Khachaturian ZS, Khachaturian AS, Thies W. The draft "national plan" to address Alzheimer's disease - National Alzheimer's Project Act (NAPA). Alzheimers Dement. 2012 ; 8 (3). 234-236
2. 2012 Alzheimer's disease facts and figures. Alzheimers Dement. 2012 ; 8 (2). 131-168
3. Bloudek LM, Spackman DE, Blankenburg M, Sullivan SD. Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer's disease. J Alzheimers Dis. 2011 ; 26 (4). 627-645
4. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001 ; 56 (9). 1143-1153
5. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work group under the auspices of Department of Health and Human Services Task Force on Alzheimer s Disease. Neurology. 1984 ; 34 (7). 939-944
6. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007 ; 6 (8). 734-746
7. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. 4 th ed. Washington, DC: American Psychiatric Association; 2000. Washington, DC: American Psychiatric Association ; 2000 :
8. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association Workgroups on Diagnostic Guidelines for Alzheimer s Disease. Alzheimers Dement. 2011 ; 7 (3). 263-269
9. Jack CR, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010 ; 9 (1). 119-128
10. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2003 ; 2 (10). 605-613
11. Group Health. Clinical review criteria: FDG PET for Alzheimer's disease/dementia. http://www.ghc.org/all-sites/clinical/criteria/pdf/petscn- alzheimer.pdf. Updated 2010. Accessed May 2, 2012.
12. Cedazo-Minguez A, Winblad B. Biomarkers for Alzheimer's disease and other forms of dementia: clinical needs, limitations and future aspects. Exp Gerontol. 2010 ; 45 (1). 5-14
13. Durand-Martel P, Tremblay D, Brodeur C, Paquet N. Autopsy as gold standard in FDG-PET studies in dementia. Can J Neurol Sci. 2010 ; 37 (3). 336-342
14. RamachadranTSZachariahSBAgrawalVKSwarnkarAGill NaulLChangHT. Alzheimer disease imaging. http://www.refworks.com/refworks2/default.aspx?r= references|MainLayout::init. Accessed May 2, 2012.
15. Yuan Y, Gu ZX, Wei WS. Fluorodeoxyglucose-positron-emission tomography, single-photon emission tomography, and structural MR imaging for prediction of rapid conversion to Alzheimer disease in patients with mild cognitive impairment: a meta-analysis. AJNR Am J Neuroradiol. 2009 ; 30 (2). 404-410
16. Jelic V, Kowalski J. Evidence-based evaluation of diagnostic accuracy of resting EEG in dementia and mild cognitive impairment. Clin EEG Neurosci. 2009 ; 40 (2). 129-142
17. The Ronald and Nancy Reagan Research Institute of the Alzheimer s Association and the National Institute on Aging Working Group. Neurobiol Aging. 1998 ; 19 (2). 109-116
18. Akobeng AK. Understanding diagnostic tests 1: sensitivity, specificity and predictive values. Acta Paediatr. 2007 ; 96 (3). 338-341
19. Haynes RB. Of studies, syntheses, synopses, summaries, and systems: The "5S" evolution of information services for evidence-based health care decisions. ACP J Club. 2006 ; 145 (3). A8
20. American College of Medical Genetics/American Society of Human Genetics Working Group on ApoE and Alzheimer Disease. JAMA. 1995 ; 274 (20). 1627-1629
21. Allan CL, Sexton CE, Welchew D, Epmeier KP. Imaging and biomarkers for Alzheimer's disease. Maturitas. 2010 ; 65 (2). 138-142
22. Andreasen N, Blennow K. CSF biomarkers for mild cognitive impairment and early Alzheimer's disease. Clin Neurol Neurosurg. 2005 ; 107 (3). 165-173
23. Andreasen N, Sjogren M, Blennow K. CSF markers for Alzheimer's disease: total tau, phospho-tau and Abeta42. World J Biol Psychiatry. 2003 ; 4 (4). 147-155
24. Bailey P. Biological markers in Alzheimer's disease. Can J Neurol Sci. 2007 ; 34 (suppl 1). S72 - S76
25. Bancher C, Jellinger K, Wichart I. Biological markers for the diagnosis of Alzheimer's disease. J Neural Transm Suppl. 1998 ; 53: 185-197
26. Deisenhammer F, Egg R, Giovannoni G, et al. EFNS guidelines on disease-specific CSF investigations. Eur J Neurol. 2009 ; 16 (6). 760-770
27. Dewan MJ, Gupta S. Toward a definite diagnosis of Alzheimer's disease. Compr Psychiatry. 1992 ; 33 (4). 282-290
28. Dougall NJ, Bruggink S, Ebmeier KP. Systematic review of the diagnostic accuracy of 99mTc-HMPAO-SPECT in dementia. Am J Geriatr Psychiatry. 2004 ; 12 (6). 554-570
29. Formichi P, Battisti C, Radi E, Federico A.. Cerebrospinal fluid tau, A beta, and phosphorylated tau protein for the diagnosis of Alzheimer's disease. J Cell Physiol. 2006 ; 208 (1). 39-46
30. Holtzman DM. CSF biomarkers for Alzheimer's disease: current utility and potential future use. Neurobiol Aging. 2011 ; 32 (suppl 1). S4 - S9
31. Jacova C, Kertesz A, Blair M, Fisk JD, Feldman HH. Neuropsychological testing and assessment for dementia. Alzheimers Dement. 2007 ; 3 (4). 299-317
32. Jagust W. Molecular neuroimaging in Alzheimer's disease. NeuroRx. 2004 ; 1 (2). 206-212
33. Jelic V, Wahlund LO. Diagnostic imaging devices in Alzheimer's disease. Expert Rev Med Devices. 2007 ; 4 (4). 475-487
34. Jellinger KA. Con: can neuropathology really confirm the exact diagnosis?. Alzheimers Res Ther. 2010 ; 2 (2). 11
35. Kantarci K, Jack CR. Neuroimaging in Alzheimer disease: an evidence-based review. Neuroimaging Clin N Am. 2003 ; 13 (2). 197-209
36. Mitchell AJ. A meta-analysis of the accuracy of the mini-mental state examination in the detection of dementia and mild cognitive impairment. J Psychiatr Res. 2009 ; 43 (4). 411-431
37. Mitchell AJ. CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer's disease: a meta-analysis of 51 studies. J Neurol Neurosurg Psychiatry. 2009 ; 80 (9). 966-975
38. Mitchell A, Brindle N. CSF phosphorylated tau - does it constitute an accurate biological test for Alzheimer's disease?. Int J Geriatr Psychiatry. 2003 ; 18 (5). 407-411
39. Patwardhan MB, McCrory DC, Matchar DB, Samsa GP, Rutschmann OT. Alzheimer disease: operating characteristics of PET - a meta-analysis. Radiology. 2004 ; 231 (1). 73-80
40. Pupi A, Mosconi L, Nobili FM, Sorbi S. Toward the validation of functional neuroimaging as a potential biomarker for Alzheimer's disease: implications for drug development. Mol Imaging Biol. 2005 ; 7 (1). 59-68
41. Silverman DH, Small GW, Phelps ME. Clinical value of neuroimaging in the diagnosis of dementia. Sensitivity and specificity of regional cerebral metabolic and other parameters for early identification of Alzheimer's disease. Clin Positron Imaging. 1999 ; 2 (3). 119-130
42. Sjogren M, Andreasen N, Blennow K. Advances in the detection of Alzheimer's disease-use of cerebrospinal fluid biomarkers. Clin Chim Acta. 2003 ; 332 (1-2). 1-10
43. Small GW, Leiter F. Neuroimaging for diagnosis of dementia. J Clin Psychiatry. 1998 ; 59 (suppl 11). 4-7
44. Sonnen JA, Montine KS, Quinn JF, Kaye JA, Breitner JC, Montine TJ. Biomarkers for cognitive impairment and dementia in elderly people. Lancet Neurol. 2008 ; 7 (8). 704-714
45. Sunderland T, Linker G, Mirza N, et al. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA. 2003 ; 289 (16). 2094-2103
46. Wahlund LO, Almkvist O, Blennow K, et al. Evidence-based evaluation of magnetic resonance imaging as a diagnostic tool in dementia workup. Top Magn Reson Imaging. 2005 ; 16 (6). 427-437
47. Waldemar G.. Functional brain imaging with SPECT in normal aging and dementia. Methodological, pathophysiological, and diagnostic aspects. Cerebrovasc Brain Metab Rev. 1995 ; 7 (2). 89-130
48. Wiltfang J, Lewczuk P, Riederer P, et al. Consensus paper of the WFSBP task force on biological markers of dementia: the role of CSF and blood analysis in the early and differential diagnosis of dementia. World J Biol Psychiatry. 2005 ; 6 (2). 69-84
49. Zakzanis KK. Quantitative evidence for neuroanatomic and neuropsychological markers in dementia of the Alzheimer's type. J Clin Exp Neuropsychol. 1998 ; 20 (2). 259-269
50. van Harten AC, Kester MI, Visser PJ, et al. Tau and p-tau as CSF biomarkers in dementia: a meta-analysis. Clin Chem Lab Med. 2011 ; 49 (3). 353-366
51. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association Workgroups on Diagnostic Guidelines for Alzheimer's Disease. Alzheimers Dement. 2011 ; 7 (3). 270-279
52. Noel-Storr AH, Flicker L, Ritchie CW, et al. Systematic review of the body of evidence for the use of biomarkers in the diagnosis of dementia [published online October 27, 2012]. Alzheimers Dement. 2012 ;:
53. Clark CM, Schneider JA, Bedell BJ, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011 ; 305 (3). 275-283
54. Zhang S, Han D, Tan X, Feng J, Guo Y, Ding Y. Diagnostic accuracy of 18 F-FDG and 11 C-PIB-PET for prediction of short-term conversion to Alzheimer's disease in subjects with mild cognitive impairment. Int J Clin Pract. 2012 ; 66 (2). 185-198
55. Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at national institute on Aging Alzheimer disease centers, 2005-2010. J Neuropathol Exp Neurol. 2012 ; 71 (4). 266-273
56. Hyman BT, Phelps CH, Beach TG, et al. National institute on Aging-Alzheimer's association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement. 2012 ; 8 (1). 1-13
57. Bossuyt PM, Reitsma JB, Bruns DE, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Ann Intern Med. 2003 ; 138 (1). 40-44